A Study to Evaluate Plasma and Sputum As Noninvasive Biomarkers for Bronchial Dysplasia Progression/Regression


About this study

This study is designed to determine whether or not plasma and sputum microRNA might be an effective, non-invasive biomarker for lung cancer risk.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Paul Limburg, M.D.

Closed for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

More information


Publications are currently not available

Mayo Clinic Footer